BB Biotech (0JYO) Ratios
BB Biotech Ratios
GB:0JYO's free cash flow for Q3 2026 was $-43.08M. For the 2026 fiscal year, GB:0JYO's free cash flow was increased by $0.00 and operating cash flow was $-43.08M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.00 | 19.88 | 158.32 | 0.01 | 0.01 |
| Quick Ratio | 0.00 | 19.88 | 158.32 | 0.01 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.03 | 0.01 | 0.01 |
| Solvency Ratio | 82.90 | 0.63 | -1.19 | -1.83 | -2.11 |
| Operating Cash Flow Ratio | 0.00 | 2.51 | 13.10 | -0.97 | -0.26 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 2.59 | 0.72 | -0.99 | -0.27 |
| Net Current Asset Value | $ 97.95M | $ 2.29B | $ 2.32B | $ -365.31M | $ -352.17M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.05 | 0.12 | 0.12 | 0.10 |
| Debt-to-Equity Ratio | 0.00 | 0.05 | 0.13 | 0.14 | 0.11 |
| Debt-to-Capital Ratio | 0.00 | 0.05 | 0.12 | 0.12 | 0.10 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 |
| Financial Leverage Ratio | 1.00 | 1.05 | 1.14 | 1.14 | 1.11 |
| Debt Service Coverage Ratio | 1306.04 | 0.66 | -0.65 | -0.98 | -1.13 |
| Interest Coverage Ratio | 1324.68 | 16.95 | -5.16 | -22.38 | -53.34 |
| Debt to Market Cap | 0.00 | 0.06 | 0.13 | 0.24 | 0.08 |
| Interest Debt Per Share | 0.01 | 2.23 | 5.67 | 6.63 | 6.43 |
| Net Debt to EBITDA | -0.17 | 1.46 | -1.51 | -1.01 | -0.87 |
| Profitability Margins | |||||
| Gross Profit Margin | 99.93% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | 753.32% | 71.96% | -98865.71% | -1075325.00% | 14.94% |
| EBITDA Margin | 753.32% | 71.96% | -575017.14% | -8932150.00% | 101.66% |
| Operating Profit Margin | 763.99% | 75.61% | -85508.57% | -965525.00% | 13.27% |
| Pretax Profit Margin | 752.75% | 68.04% | -590080.00% | -8943775.00% | 102.15% |
| Net Profit Margin | 752.66% | 67.99% | -590305.71% | -8945300.00% | 102.17% |
| Continuous Operations Profit Margin | 752.66% | 67.99% | -590305.71% | -8945300.00% | 102.17% |
| Net Income Per EBT | 99.99% | 99.93% | 100.04% | 100.02% | 100.02% |
| EBT Per EBIT | 98.53% | 89.99% | 690.08% | 926.31% | 769.54% |
| Return on Assets (ROA) | 20.75% | 3.15% | -7.83% | -11.72% | -11.11% |
| Return on Equity (ROE) | 20.81% | 3.32% | -8.89% | -13.32% | -12.33% |
| Return on Capital Employed (ROCE) | 21.07% | 3.69% | -1.14% | -1.44% | -1.60% |
| Return on Invested Capital (ROIC) | 21.06% | 3.51% | -0.54% | -1.27% | -1.45% |
| Return on Tangible Assets | 20.75% | 3.15% | -7.83% | -11.72% | -11.11% |
| Earnings Yield | 23.45% | 3.90% | -8.82% | -11.78% | -9.48% |
| Efficiency Ratios | |||||
| Receivables Turnover | 13.93 | 0.00 | 0.02 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.03 | 0.05 | 0.00 | 0.00 | -0.11 |
| Working Capital Turnover Ratio | 0.06 | 0.05 | 0.00 | -0.00 | -0.22 |
| Cash Conversion Cycle | 26.20 | 0.00 | 19073.86 | 0.00 | 0.00 |
| Days of Sales Outstanding | 26.20 | 0.00 | 19073.86 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 26.20 | 0.00 | 19073.86 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 5.64 | 5.54 | 3.98 | -6.50 | -1.71 |
| Free Cash Flow Per Share | 5.64 | 5.54 | 3.98 | -6.50 | -1.71 |
| Dividend Paid and CapEx Coverage Ratio | 3.14 | 2.78 | 1.40 | -1.69 | -0.48 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 2.59 | 0.72 | -0.99 | -0.27 |
| Operating Cash Flow to Sales Ratio | 4.02 | 2.73 | 6236.46 | -89453.00 | 0.24 |
| Free Cash Flow Yield | 12.54% | 15.64% | 9.32% | -11.78% | -2.22% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 4.26 | 25.65 | -11.34 | -8.49 | -10.55 |
| Price-to-Sales (P/S) Ratio | 32.10 | 17.44 | 66937.95 | 759151.80 | -10.78 |
| Price-to-Book (P/B) Ratio | 0.89 | 0.85 | 1.01 | 1.13 | 1.30 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 7.97 | 6.39 | 10.73 | -8.49 | -45.06 |
| Price-to-Operating Cash Flow Ratio | 7.97 | 6.39 | 10.73 | -8.49 | -45.06 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | -0.19 | 0.27 | 0.77 | 0.07 |
| Enterprise Value Multiple | 4.09 | 25.69 | -13.15 | -9.51 | -11.48 |
| Enterprise Value | 2.37B | 2.06B | 2.65B | 3.40B | 4.62B |
| EV to EBITDA | 4.09 | 25.69 | -13.15 | -9.51 | -11.48 |
| EV to Sales | 30.82 | 18.49 | 75635.06 | 849414.80 | -11.67 |
| EV to Free Cash Flow | 7.66 | 6.78 | 12.13 | -9.50 | -48.78 |
| EV to Operating Cash Flow | 7.66 | 6.78 | 12.13 | -9.50 | -48.78 |
| Tangible Book Value Per Share | 50.67 | 41.57 | 42.39 | 48.83 | 59.41 |
| Shareholders’ Equity Per Share | 50.67 | 41.57 | 42.39 | 48.83 | 59.31 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 1.40 | 2.03 | 0.00 | 0.00 | -7.16 |
| Net Income Per Share | 10.54 | 1.38 | -3.77 | -6.50 | -7.31 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 0.95 | 5.97 | 8.32 | 6.84 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.24 | 120.77 | 1034.25 | -0.02 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.00 | 0.00 | -1.06 | 1.00 | 0.23 |
Currency in CHF
